USA - engelsk - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - estrogens, esterified (unii: 3asp8q3768) (estrogens, esterified - unii:3asp8q3768), methyltestosterone (unii: v9efu16zif) (methyltestosterone - unii:v9efu16zif) - estrogens, conjugated 0.625 mg - esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (there is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. should not be used in women with any of the following conditions: 1. undiagnosed abnormal genital bleeding. 2. known, suspected, or history of cancer of the breast. 3. known or suspected estrogen-dependent neoplasia. 4. active deep vein thrombosis, pulmonary embolism or history of these conditions. 5. active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction). 6. liver dysfunction or disease. 7. esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. should not be used in patients with known hypersensitivity to its ingredients. 8. known or suspected pregnancy. there is no indication for esterified estrogens and methyltestosterone tablets and esterified estrogens and methyltestosterone tablets h.s. in pregnancy. there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions . ) methyltestosterone should not be used in: 1. the presence of severe liver damage. 2. pregnancy and in breast-feeding mothers because of the possibility of masculinization of the female fetus or breast-fed infant.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.3 mg - tablet, film coated - excipient ingredients: sucrose; hyprolose; macrogol 400; carnauba wax; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; polysorbate 80; quinoline yellow aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1. premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 625microgram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 625microgram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - conjugated oestrogens - oral tablet - 1.25mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - conjugated oestrogens - oral tablet - 1.25mg

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - conjugated oestrogens - oral tablet - 625microgram

Israel - engelsk - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - bazedoxifene acetate; estrogens conjugated - tablets modified release - bazedoxifene acetate 20 mg; estrogens conjugated 0.45 mg - conjugated estrogens and bazedoxifene - treatment of the following conditions in women with a uterus:• treatment of moderate to severe vasomotor symptoms associated with menopause• prevention of postmenopausal osteoporosis

USA - engelsk - NLM (National Library of Medicine)

seton pharmaceuticals - estrogens, conjugated (unii: iu5qr144qx) (estrogens, conjugated - unii:iu5qr144qx) - estrogens, conjugated 0.625 mg